Novolog Mix 70/30
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
General Information
Novolog Mix is an insulin analog premix containing 30%
rapid-acting insulin aspart and 70% that has been modified into a
long-acting formulation. It has been approved in a subcutaneous
injection formulation, for the control of hyperglycemia.
Hyperglycemia is an abnormally increased content of sugar in the
blood.
Diabetes is a chronic disease that requires a combination of
professional medical care and self-management through strict
attention to diet, self-medication, and frequent monitoring
one's blood sugar level.
Clinical Results
Approval of NovoLog Mix 70/30 is based on results from clinical
trials evaluating glycaemic control in subjects with type 1 and 2
diabetes.
Side Effects
Adverse events associated with the use of human insulin therapy
include (but are not limited to) the following:
- Injection site reaction
- Lipodystrophy
- Pruritus
- Rash
- Hypoglycemia
Mechanism of Action
NovoLog Mix 70/30 regulates glucose metabolism. Insulins,
including Novolog Mix, bind to insulin receptors on muscle and fat
cells. They lower blood glucose by facilitating the cellular uptake
of glucose, while simultaneously inhibiting the output of glucose
from the liver.
Additional Information
For additional information on Novolog Mix 70/30, please visit
Novo
Nordisk.
